

ALLG Trial Number:	MM20
Trial Name:	
A Multicentre Phase 3 Trial Comparing Elotuzumab-Cyclophosphamide-Thalidomide-Dexamethasone (E-CTD) with Cyclophosphamide-Thalidomide-Dexamethasone (CTD) for the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM)	
Lay Summary:	
<p>Multiple Myeloma (MM) a common hematologic malignancy of plasma cells, is both a clinically and biologically heterogeneous disease. Since the introduction of novel agents into clinical practice, median survival of patients with MM has improved by 50%. Despite the availability of these novel agents, the disease trajectory varies for each patient, but relapses are inevitable and many patients become refractory to treatments.</p> <p>Elotuzumab is a manufactured protein directed against a target found on multiple myeloma cells. Elotuzumab was observed to kill myeloma cells in laboratory studies, and results of earlier clinical studies in patients with myeloma showed encouraging results when used in combination with lenalidomide and dexamethasone. Thalidomide is a more readily available drug from the same family as lenalidomide.</p> <p>MM20 is a phase 3 trial that will examine the efficacy and tolerability of Elotuzumab when combined with cyclophosphamide (C), thalidomide (T) and dexamethasone (D) (E-CTD) when compared to a standard CTD with relapsed/refractory MM patients.</p>	
Participating Hospitals:	
1. Alfred / 2. Austin Health / 3. Calvary Mater Newcastle / 4. Canberra / 5. Royal Adelaide / 6. Tamworth / 7. Tweed	
Target Accrual (International):	n/a
Target Accrual (ALLG):	300 (Randomised)
Expected Final Accrual Date:	December 2020